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Abstract
Background—In patients with HF and preserved ejection fraction (HFpEF), little is known 
about the characteristics of and outcomes in those with and without diabetes.
Methods—We examined clinical and echocardiographic characteristics and outcomes in the 
Irbesartan in Heart Failure with Preserved Ejection Fraction trial (I-Preserve), according to 
history of diabetes. Cox regression models were used to estimate hazard ratios (HR) for
cardiovascular outcomes adjusted for known predictors, including age, sex, natriuretic peptides, 
and comorbidity. Echocardiographic data were available in 745 patients and were additionally 
adjusted for in supplementary analyses.
Results—Overall, 1134 of 4128 patients (27%) had diabetes. Compared to those without 
diabetes, they were more likely to have a history of myocardial infarction (28% vs. 22%), higher 
BMI (31kg/m2 vs. 29kg/m2), worse Minnesota living with HF score (48 vs. 40), higher median 
NT-proBNP concentration (403 vs 320 pg/ml; all p<0.01), more signs of congestion but no 
significant difference in LVEF. Patients with diabetes had a greater left ventricular (LV) mass 
and left atrial area than patients without diabetes. Doppler E wave velocity (86 vs 76 cm/sec, 
p<0.0001) and the ratio of E/e' (11.7 vs 10.4, p=0.010) were higher in patients with diabetes.
Over a median follow-up of 4.1 years, cardiovascular death or HF hospitalization occurred in 
34% of patients with diabetes vs. 22% of those without diabetes; adjusted HR 1.75 (95% CI 
1.49-2.05) and 28% vs. 19% of patients with and without diabetes died; adjusted HR 1.59 (1.33-
1.91).  
Conclusions—In HFpEF, patients with diabetes have more signs of congestion, worse quality of 
life, higher NT-proBNP levels, and a poorer prognosis. They also display greater structural and 
functional echocardiographic abnormalities. Further investigation is needed to determine the 
mediators of the adverse impact of diabetes on outcomes in HFPEF, and whether they are 
modifiable.
Clinical Trial Registration—http://www.clinicaltrials.gov Unique Identifier NCT00095238 
Key-words: heart failure; diabetes mellitus; echocardiography
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Clinical Perspective
What is new? 
? Among individuals with heart failure and preserved ejection fraction (HFpEF), those 
with diabetes have more evidence of congestion and higher N-terminal pro B-type 
natriuretic peptide (NT proBNP) concentrations, compared to HFpEF patients without 
diabetes.
? The former patients also reported worse health-related quality of life and had a higher 
risk of cardiovascular mortality and hospitalization. 
? They also had more structural and functional echocardiographic abnormalities, 
including evidence of elevated left ventricular filling pressure which may, at least in 
part, mediate the adverse consequences of diabetes in patients with HFpEF.
What are the clinical implications? 
? The study underlines the need for further investigation of which treatment approaches to 
both heart failure and diabetes might improve outcomes in patients with both conditions.  
? The finding of more signs of congestion, higher NT proBNP levels and 
echocardiographic evidence of higher filling pressures in patients with diabetes, 
compared to those without, raises the possibility that more intensive diuretic therapy 
might be therapeutically helpful, although this hypothesis needs to be tested, 
prospectively, in a clinical trial.
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Introduction
Diabetes is common in patients with heart failure and preserved ejection fraction (HFpEF). It has 
been suggested that diabetes plays a central pathophysiological role in the development of 
HFpEF, although the exact mechanisms are debated and there are few comparative data on 
cardiac structure and function in HFpEF patients with and without diabetes.1-4 Also, while it is 
well known that diabetes is associated with worse outcomes in patients with heart failure and 
reduced ejection fraction (HFrEF), less is known clinical and echocardiographic characteristics 
of, and outcomes in, HFpEF patients with diabetes compared to those without.1-3 The importance 
of better understanding the relationship between diabetes and heart failure has been underscored 
by recent trials in patients with type 2 diabetes mellitus which have suggested that some drugs 
may increase the risk of heart failure (thiazolidinediones and possibly certain dipeptidyl-
peptidase-4 inhibitors)4-6 and others may decrease the risk (the sodium glucose cotransporter 2 
inhibitor empagliflozin).7 Three GLP-1 agonist trials have shown no clear cut effect on heart 
failure.8-10 The aforementioned trials largely reported incident heart failure and there are few data 
on the effect of anti-diabetes drugs in patients with established heart failure. One notable 
exception is a recent trial demonstrating no benefit of liraglutide in patients with HFrEF recently 
hospitalized with decompensation.11
 Although the type of HF affected by these treatments was not characterized in any of the 
trials mentioned, it is likely that many or even most cases were HFpEF.12 With this study we 
aimed to give clinicians a better understanding of the consequences of diabetes in patients with 
HFpEF and to give insight into potential pathophysiologic mechanisms and therapeutic targets 
for future research.
 by guest on January 5, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.116.024593
5 
 In the present study, we examined the risk of adverse cardiovascular outcomes according 
to diabetes status adjusted for known risk factors in the Irbesartan in Heart Failure with 
Preserved Ejection Fraction trial (I-Preserve). In a subgroup of patients, a full echocardiographic
examination was performed13 which allowed a detailed comparison of cardiac structure and 
function in HFpEF patients with and without diabetes. 
Methods
I-Preserve was a randomized trial that examined the effects of the angiotensin II receptor 
antagonist, irbesartan, on morbidity and mortality in patients with HFpEF.14 The rationale, 
design, and findings from I-Preserve have previously been reported.14-16 Briefly, patients enrolled 
in the trial were ?60 years of age and had HF symptoms and a left ventricular ejection fraction 
(LVEF) ???????????????????????????????????????????????????????????????????????????????????
months were required to have current New York Heart Association (NYHA) class II, III, or IV 
symptoms and echocardiographic, electrocardiographic or chest X-ray findings supporting a 
diagnosis of heart failure and/or underlying cardiac disease. If they had not been recently 
hospitalized for HF, they were required to have ongoing class III or IV symptoms with the 
corroborative evidence described above. The corroborative evidence required was at least one of 
pulmonary congestion on a chest x-ray, left ventricular hypertrophy and/or an enlarged left 
atrium on an echocardiogram and left ventricular hypertrophy or left bundle branch block on an 
ECG. The details of these criteria have been described previously.14
 Angiotensin-converting enzyme (ACE) inhibitor therapy was limited to those patients 
with a specific indication other than hypertension (such as diabetes mellitus with complications 
and significant coronary or peripheral artery disease). In addition, only one third of randomized 
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patients at each site were permitted to be treated with an ACE inhibitor. Treatment by an 
angiotensin II receptor blocker (ARB) was prohibited although a patient could be enrolled if 
ARB treatment was discontinued at least 14 days earlier. Exclusion criteria included a systolic 
blood pressure <100mmHg or >160mmHg or a diastolic blood pressure >95mmHg despite 
antihypertensive therapy; a creatinine level >2.5mg/dl [221??????] or a potassium concentration 
>5.2 mmol/l. The ethics committee of each of the 293 participating sites in 25 countries 
approved the trial and all patients provided informed consent. Detailed echocardiographic 
measurements were made in a subset of 745 patients at baseline, as described previously.8 
Cardiovascular outcomes and all-cause mortality did not differ between patients randomly 
assigned to irbesartan or placebo.15
Outcomes
For this report, the primary outcome examined was the composite of cardiovascular death or HF 
hospitalization, as well as each of the components of this composite, separately. This composite 
was slightly different from the original primary outcome of I-Preserve which was all-cause 
mortality or protocol-specified cardiovascular hospitalization (HF, myocardial infarction, stroke, 
unstable angina, ventricular or atrial dysrhythmia) but in keeping with the primary composite 
outcome of most recent HF trials. We also report all-cause mortality. All deaths and 
hospitalizations were adjudicated by an independent end-point committee. 
Statistical analyses 
Baseline characteristics are presented as means with standard deviations for continuous variables 
and frequencies and percentages for categorical variables. Differences in baseline characteristics 
according to diabetes were assessed using a chi-squared test for categorical covariates and two-
sided t-tests and kruskall-wallis test, as appropriate. Tests for interactions between diabetes and 
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age, sex and ischemic etiology were performed but none were significant.  Incidence rates of the 
outcomes of interest are presented per 100 person-years, and the risks of HF hospitalization, 
cardiovascular death and the composite outcome were estimated as HRs in Cox regression 
models with those with no history of diabetes used as reference. The adjusted model included 
variables previously validated for the I-Preserve study16; age, sex, quality of life, hospitalization 
for HF in last 6 months, LVEF, heart rate, ischemic etiology, eGFR, NT-proBNP (log-
transformed), neutrophils (log-transformed), chronic obstructive pulmonary disease 
(COPD)/asthma, and previous myocardial infarction. The outcomes of interest were also 
assessed by cumulative incidence plots using the Nelson Aalen method. We also conducted 
competing risk analyses for all non-fatal events (and for CV death the competing risk of all-
cause death) using the Fine and Gray approach.for the subdistribution of a competing risk.17 As a 
supplementary analysis, we stratified patients with diabetes according to insulin use and non-use, 
respectively.
In patients with echocardiographic measurements available, we further adjusted for left 
ventricular (LV) systolic and diastolic properties as well as measurements of LV structure. These 
results are presented separately as a subgroup analysis. To explore the potential for overfitting of 
the model with echocardiographic data which was only available in a subset of patients we 
conducted sensitivity analyses. In the first, we removed end-systolic left atrial area and left 
ventricular mass from the model and in the second, we calculated a single continuous risk score 
variable from the previously described multivariable risk score for I-Preserve, and added this to a 
model with the echocardiographic measurements. We did not adjust for randomization arm as 
irbesartan had no effect on any outcome in I-Preserve, and no interaction with diabetes was 
found. All p values are two-sided, and a p value of <0.05 was considered significant. All 
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analyses were performed separately using Stata version 14 (Stata Corp. College Station, Texas, 
USA). 
Results
Baseline characteristics
Overall, 1134 (27%) of 4128 patients enrolled in I-Preserve had a diagnosis of diabetes at 
baseline. The characteristics of patients with and without diabetes at baseline are shown in Table 
1. Patients with diabetes were slightly younger and had higher heart rate and body mass index 
(BMI), but not statistically different blood pressure and renal function. Furthermore, patients 
with diabetes had higher NT-proBNP, despite no difference in LVEF and prevalence of atrial 
fibrillation. They were more likely to have an ischemic etiology, were about twice as likely to 
have undergone percutaneous coronary intervention or coronary artery bypass grafting (20% vs. 
11%) and were more likely to have had a stroke. Although patients with and without diabetes did 
not differ in distribution of NYHA class, those with diabetes had a significantly worse quality of 
life as measured by the Minnesota Living with Heart Failure score.  Background use of 
medications was comparable, except for ACE inhibitor and lipid-lowering drugs, both of which 
were more common in patients with diabetes. Signs and symptoms of HF as well as 
electrocardiographic findings of left ventricular (LV) hypertrophy, left bundle branch block and 
atrial fibrillation/flutter did not differ significantly between those with and without diabetes at 
baseline.
Echocardiographic measurements
Of the 745 patients in the echocardiographic substudy, 187 (25%) had diabetes (Table 2). The 
echocardiographic data were incomplete, especially for certain measurements of diastolic 
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function. We had a measurement of LVEF in all 745 patients, left atrial area in 696 and end-
systolic LV volume in 581 patients. E/A ratio was available in 647 patients but E/e ratio was 
available in only 515 patients. The baseline characteristics of this subset of patients are presented 
in Supplementary Table 1. The differences between patients with and without diabetes in this 
subset reflected those in the overall trial. 
In terms of LV structure, patients with diabetes had a larger end systolic dimension 
(3.3±0.7 vs. 3.2±0.7 cm, p=0.02), end-diastolic dimension (4.9 ±0.6 vs 4.8±0.6 cm, p=0.044) and 
greater LV mass (173±48 vs. 161±48 grams, p=0.004), but the relative wall thickness was 
similar (0.40±0.08 vs. 0.40±0.08, p=0.40). No significant differences were seen for LV systolic 
properties, although fractional shortening tended to be lower in diabetic patients (33±10% vs. 
35±10% p=0.09). 
Details of LV diastolic function are shown in Table 2. Early diastolic mitral inflow 
velocity (E) was significantly higher in patients with diabetes (86±32 vs 76±27 cm/sec, 
p=<0.0001), as was the ratio of E/e' (11.7 vs 10.4, p=0.001), where e' is the average of lateral and 
septal annular velocities by tissue Doppler. There were 27% of patients with diabetes and 14% of 
those without with an E/e'avg >14 (p=0.001) suggesting significantly more diastolic dysfunction 
among patients with diabetes.18 E/A was also higher among patients with diabetes (1.18±0.97 vs 
1.00±0.65, p=0.01). Left atrial area was greater (24±6 vs. 23±6 cm2, p=0.003), as were the 
proportion of individuals with an enlarged left atrium (75 vs. 66%, P=0.02), all compared to 
patients without diabetes.
Clinical Outcomes
The unadjusted rates of the composite endpoint of cardiovascular death and HF hospitalization 
and all-cause mortality were higher in patients with diabetes (Table 3 and Figure 1 and 2).
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Over a median of 4.1 years of follow-up, the composite endpoint occurred in 391 of patients 
(34%) with diabetes compared with 662 of those without (22%), with event rates per 100 person 
years of 10.2 and 5.7, respectively. After adjustments for known predictive variables (see 
Methods), the hazard ratio (HR) for patients with diabetes, compared to those without, was 1.75 
(95% CI 1.49-2.05). Competing risk analyses gave comparable results (Supplementary Appendix 
Table 2). The pattern of higher risk associated with diabetes (HR 1.79 [1.28-2.51] for the 
composite endpoint) was also seen in the echocardiography subgroup, although this risk was no 
longer statistically significant (HR 1.45 [0.82-2.59]) after further adjustment for 
echocardiographic variables (see Methods and Table 4) possibly due to the smaller sample size.
The results of the sensitivity analyses of the models that included echocardiographic data 
showed similar results. 
Diabetes was associated with higher rates of all-cause death, as well as cardiovascular death and 
non-cardiovascular death. The elevated risks of these outcomes persisted after adjustments for 
known prognostic variables (Table 3). Mode of death according to the presence or absence of 
diabetes is depicted in Table 5. Pump failure and sudden cardiac death were more frequent in 
patients with diabetes, whereas rates of fatal myocardial infarction and stroke were similar.
HF hospitalization occurred in 253 patients (22%) with diabetes, compared to 408 patients (14%) 
without diabetes, yielding event rates per 100 person-years of 6.6 and 3.5, giving a diabetes/no 
diabetes adjusted hazard ratio of 1.77 (1.45-2.16). When repeat HF hospitalizations were 
included, 708 admissions occurred in those with diabetes and 468 in individuals without 
diabetes, resulting in event rates per 100 person-years of 9.3 and 5.7, respectively. The number 
and rates of admission to hospital for any reason, and for cardiovascular and non-cardiovascular
reasons separately, were also higher in individuals with diabetes compared to those without 
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(Table 3). Results stratified by use/non-use of insulin treatment in patients with diabetes are
shown in Supplementary Table 3, which displays a step-wise worsening, with the highest risk in 
patients with diabetes who were insulin-treated.
Adverse events 
Serious adverse events and drug discontinuation due to adverse events (excluding death) are 
listed in Supplementary Appendix Table 4. Overall, serious adverse events were rare, but 
increased potassium, chronic kidney disease and cough were more prevalent in patients with 
diabetes (all p-values<0.05). Drug discontinuation due to adverse events other than death was 
also more likely in patients with diabetes (23% vs. 17%, p-value 0.0008).  
Discussion
There is only one other report from a large clinical trial comparing the characteristics of, and 
outcomes in, HFpEF patients with and without diabetes mellitus.   However, in that publication 
from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity 
(CHARM) Programme, a LVEF cut-point of 40% was used, natriuretic peptides were not 
measured, echocardiography data were unavailable and health-related quality of life was not 
reported.5 In the present study we fill these gaps and describe a number of novel findings. We 
found that patients with diabetes, despite no statistically significant differences in age, sex 
distribution, and average LVEF, had a different pattern of comorbidity/etiology (more coronary 
heart disease/less hypertension), a higher median NT-proBNP (despite a greater prevalence of 
obesity), more evidence of congestion, worse quality of life, and more cardiac remodelling with 
higher LV mass and more evidence of diastolic dysfunction than patients without diabetes. 
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Additionally, we found that the relationship between diabetes and higher risk of cardiovascular 
outcomes persisted after adjustment for NT-proBNP. 
It was notable that despite a similar distribution of NYHA class and LVEF, variables 
commonly used to characterise the severity of heart failure, patients with diabetes had a higher 
(worse) Minnesota Living with Heart Failure score with values similar to those found in HFrEF 
patients with diabetes. The differential between HFpEF patients with and without diabetes in I-
Preserve (48 vs 40) was very similar to that seen in another study of the effects of 
phosphodiesterase-5 inhibition in HFpEF: patients without diabetes (n=123) had a mean score of 
42 vs patients with diabetes (n=93) who had a mean score of 47.19 This worse self-reported heart 
failure-related quality of life may have a number of explanations one of which may be the greater 
severity of congestion documented by edema, rales, and jugular venous distension in patients 
with diabetes (and supported by greater diuretic use, elevated natriuretic peptides and left atrial 
enlargement – see below). The phosphodiesterase-5 inhibitor trial mentioned above also found 
more edema in patients with diabetes and those patients had reduced functional capacity 
compared to patients without diabetes. That patients with diabetes exhibit more congestion may 
be relevant to the increased risk of heart failure with hypoglycemic drugs causing sodium and 
water retention (thiazolidinediones) and reduced risk with those acting as a diuretic (sodium-
glucose cotransporter-2 inhibitors).12,18 These findings might also help decide in which patients 
to target new treatments in HFpEF, depending on their mode of action. The substantially worse 
Minnesota Living with Heart Failure score in patients with HFpEF and diabetes also suggests 
that health-related quality of life may be a worthwhile endpoint in future trials in these patients.
 Also notable was the considerably higher median NT-proBNP concentration in patients 
with diabetes, especially given the greater prevalence of obesity which is associated with lower 
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natriuretic peptide concentrations.19 Again, there may be a number of explanations for this. 
Greater congestion, as alluded to above may be one. Impaired renal function (which was slightly 
more common in patients with diabetes) may be another. Atrial fibrillation was not more 
common in patients with diabetes but those patients did have more functional and structural 
cardiac abnormalities than patients without diabetes.
 The echocardiography sub-study from I-Preserve provides some of the most unique data 
in the present report. Specifically, patients with diabetes had slightly larger left ventricular 
dimensions and greater left ventricular mass compared to patients without diabetes. This last 
finding, along with the differences we found in mitral inflow and tissue Doppler measurements, 
suggest increased LV stiffness, impaired LV filling and higher left atrial pressure (supported by 
higher NT proBNP concentrations) in patients with diabetes compared to those without.20 The 
phosphodiesterase-5 inhibitor trial also reported echocardiographic findings which were largely 
consistent with ours although the differences between patients with and without diabetes were 
less often significant, possibly because of the small sample size. One community-based cohort 
study also reported that HFpEF patients with diabetes had a greater left ventricular mass and 
higher E/e’ than patients without diabetes.20 Collectively, however, the differences in diastolic 
function between patients with and without diabetes in our study and the other studies mentioned 
were relatively modest, despite the prevalent view that diastolic dysfunction is a pathognomonic 
feature of diabetes-related cardiac disease.  
 Finally, we found that HFpEF patients with diabetes had worse outcomes than HFpEF 
patients without diabetes. This was also true in the CHARM Programme and the Digitalis 
Investigators Group trial (DIG) ancillary study in patients with a LVEF >45% (285 of the 987 
patients had diabetes).7 In the Olmsted county epidemiological study, diabetes was 
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independently predictive of death (and cardiovascular death) in a community heart failure cohort, 
irrespective of ejection fraction.21 However, unlike in these earlier trials we were able to adjust 
outcomes for NT proBNP levels. Despite adjustment for NT-proBNP as well as other prognostic 
variables, patients with diabetes were 1.5 to 2.0 times as likely to have an adverse clinical 
outcome. In contrast, we found that after additional adjustment for LV end-systolic volume, LV 
mass, E/e’, and left atrial area in the echocardiographic subgroup, the risk associated with 
diabetes was no longer statistically significant (Table 4), possibly due either to the smaller 
sample size of the echocardiographic subgroup or because adverse LV remodelling is an 
important mediator of the risk associated with diabetes. The excess risk associated with diabetes 
was seen for each of death and heart failure hospitalization and was apparent for both 
cardiovascular and non-cardiovascular death i.e. there was no specific type of event that seemed 
to be particularly increased in patients with diabetes. Adjustment for echocardiographic findings 
did not attenuate the risk of non-CV outcomes.
 Our study has a number of limitations. The analyses were retrospective rather than pre-
planned.  The diagnosis of diabetes was investigator-reported and not standardised. Although 
similar to that in DIG and CHARM trials, the prevalence of diabetes in I-Preserve was lower 
than in most more recent trials, presumably reflecting the steadily increasing prevalence of 
diabetes.2, 22  The small numbers of events in those with echocardiographic data may have led to 
“overfitting” of the model, although sensitivity analyses found similar results after removing 
variables from the model. Finally, patient selection in clinical trials limits the external validity of 
findings when extrapolating to a typical community population.
 In summary, among patients with HFpEF, those with diabetes have more signs of 
congestion, worse quality of life, higher NT-proBNP levels, greater structural and functional 
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echocardiographic abnormalities and worse outcomes than those without diabetes. Further 
investigation is needed to determine the mediators of the adverse impact of diabetes on outcomes 
in HFpEF, and whether they are modifiable.  
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Table 1. Baseline Characteristics stratified by presence of diabetes in I-Preserve
All patients
N=4128 
No diabetes
n=2994 
Diabetes
n=1134 
P-value
Age, mean – years 72 ± 7 72 ± 7 71 ± 7 0.0006
>/=65 years 1975 (48%) 1444 (48%) 531 (47%) 0.12
>/=75 years 1413 (34%) 1036 (35%) 377 (33%)
Female sex, no. (%) 2491 (60%) 1802 (60%) 689 (61%) 0.74
Race, no (%): <0.0001
Caucasian 3859 (94%) 2829 (95%) 1030 (91%)
Black 82 (2%) 47 (2%) 35 (3%)
Other 187 (4%) 118 (4%) 69 (6%)
Ejection fraction 59 ± 9 59 ± 9 60 ± 9 0.45
Body mass index 30 ± 5 29 ± 5 31 ± 6 <0.0001
Underweight (<18.5) 20 (1%) 20 (1%) 0 (0%) <0.0001
Normal (18.5-24.9) 624 (15%) 514 (17%) 110 (10%)
Overweight (25-29.9) 1744 (42%) 1311 (44%) 433 (38%)
??????????? 1740 (42%) 1149 (38%) 591 (52%)
Symptoms
NYHA class 0.07
I 1 (0%) 0 (0%) 1 (0%)
II 870 (21%) 653 (22%) 217 (19%)
III 3144 (76%) 2264 (76%) 880 (78%)
IV 112 (3%) 76 (3%) 36 (3%)
Minnesota living with HF score 42 (28-58) 40 (27-55) 48 (30-55) <0.0001
Examination findings
Rales 1158 (28%) 811 (27%) 347 (31%) 0.0250
CXR congestion 1590 (39%) 1086 (36%) 505 (44%) <0.0001
Jugular venous distention 346 (8%) 229 (8%) 117 (10%) 0.0060
Edema 2255 (55%) 1609 (54%) 646 (57%) 0.0631
3rd heart sound 338 (8%) 227 (8%) 111 (10%) 0.0217
Heart rate /bpm 71 ± 10 71 ± 10 72 ± 10 <0.0001
Systolic blood pressure /mm Hg 136 ± 15 136 ± 15 137 ± 15 0.64
ECG findings
Left bundle branch block 336 (8%) 247 (8%) 89 (8%) 0.67
Left ventricular hypertrophy 1260 (31%) 934 (31%) 326 (29%) 0.13
QRS duration, (no pacemaker) 0.10 ± 0.05 0.10 ± 0.06 0.10 ± 0.06 0.1784
Atrial fibrillation/flutter 697 (17%) 497 (17% 200 (18%) 0.47
Laboratory measurements
NT-proBNP, median (Q1-Q3) 339 (134-964) 320 (128-945) 403 (154-1023) 0.0074
eGFR – l/min/1.73m2 70 (55-85) 70 (56-84) 69 (53-86) 0.3362
CKD (eGFR<60 l/min/1.73m2) 1363 (33%) 962 (32%) 401 (35%) 0.0488
Hemoglobin, g/dl 14.0 ± 1.5 14.1 ± 1.4 13.8 ± 1.6 <0.0001
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Anemia (<11 women/ <13 men) 514 (13%) 161 (5%) 119 (11%) <0.0001
Neutrophils, cells/μL (Q1-Q3) 4.3 (3.4-5.3) 4.2 (3.3-5.2) 4.6 (3.7-5.6) <0.0001
Medical history, no. (%)
HF hospitalization within 6 
months
1816 (44%) 1294 (43%) 522 (46%) 0.1042
Ischemic etiology 1036 (25%) 710 (24%) 326 (29%) 0.0009
Hypertensive etiology 2622 (64%) 1960 (66%) 662 (58%) <0.0001
Myocardial infarction 969 (23%) 655 (22%) 314 (28%) <0.0001
Stable angina pectoris 1652 (40%) 1217 (41%) 435 (38%) 0.1804
Unstable angina pectoris 315 (8%) 197 (7%) 118 (10%) <0.0001
Hypertension 3650 (88%) 2625 (88%) 1025 (90%) 0.0150
Atrial fibrillation 1209 (29%) 868 (29%) 341 (30%) 0.50
Stroke 399 (10%) 263 (9%) 136 (12%) 0.002
COPD/Asthma 391 (10%) 262 (9%) 129 (11%) 0.0101
PCI or CABG 548 (13%) 327 (11%) 221 (20%) <0.0001
ICD 12 (0%) 6 (0%) 6 (1%) 0.08
Pacemaker 252 (6%) 168 (6%) 84 (7%) 0.0314
Medication, no. (%)
Any diuretic 3418 (83%) 2462 (82%) 956 (84%) 0.11
Loop diuretic 2150 (52%) 1480 (50%) 670 (59%) <0.0001
ACE inhibitor 1033 (25%) 615 (21%) 418 (37%) <0.0001
Beta-blocker 2427 (59%) 1774 (59%) 653 (58%) 0.33
Calcium-channel blocker 1637 (40%) 1179 (39%) 458 (40%) 0.55
Long-acting nitrates 1108 (27%) 775 (26%) 333 (29%) 0.02
Mineralocorticoid antagonists 633 (15%) 451 (15%) 182 (16%) 0.43
Digoxin 561 (14%) 390 (13%) 171 (15%) 0.09
Lipid lowering drugs 1047 (25%) 667 (22%) 380 (34%) <0.0001
Antiplatelets, any 2416 (59%) 1723 (58%) 693 (61%) 0.04
Metformin 284 (7%) 0 (0%) 284 (25%) <0.0001
Other oral antidiabetic agents 544 (13%) 2 (0%) 542 (48%) <0.0001
Insulin 339 (8%) 0 (0%) 339 (30%) <0.0001
HF – heart failure, CXR – chest x-ray, bpm – beats per minute, eGFR – estimated glomerular filtration 
rate, CKD – chronic kidney disease, PCI – percutaneous coronary intervention, CABG  - coronary artery 
bypass graft, ICD – Implantable cardioverter defibrillator. NT-pro BNP was available for 3479 (84%) of 
patients and Minnesota living with HF for 3181 patients (77%). 
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Table 2. Echocardiographic data according to diabetes status
No diabetes
n=558 
Diabetes
n=187
p-value Normal 
Range 
Age 72±7 72±7 0.97
Female 351 (63%) 108 (58%) 0.21
LV structure
End-diastolic dimension, cm 4.8±0.6 4.9±0.6 0.044 4.0-6.0
End-diastolic volume, mL 93±38 98±38 0.15 80-180
End-systolic dimension, cm 3.2±0.7 3.3±0.7 0.02 2.0-4.0
End-systolic volume, ml 34±18 37±19 0.074 25-50
Septum wall thickness, cm 0.97±0.16 1.00±0.16 0.04 0.8-0.9
Mass g 161±48 173±48 0.004 80-140
Relative wall thickness 0.40±0.08 0.40±0.08 0.40 0.36-0.40
LV hypertrophy 384 (69%) 147 (79%) 0.01
LV systolic properties
Fractional shortening, % 35±10 33±10 0.09 30-45
Ejection fraction, % 64±9 63±10 0.13 55-75
Stroke volume, mL 59±24 61±25 0.405 50-70
S´ lateral 8.2±2.3 8.2±2.3 0.72 6-14
LV diastolic properties
Diastolic dysfunction 0.30
Grade I 194(38%) 54 (32%)
Grade II 28 (6%) 14 (8%)
Grade III 282 (55%) 95 (57%)
Grade IV 7 (1%) 4 (2%)
E, cm/sec 76±27 86±32 <0.0001 40-90
E/e´lateral ratio 9.5±3.9 10.5±5.9 0.03 4.5-11.5
E/e´averageratio 10.4±3.9 11.7±6.4 0.001 <10
A, cm/sec 82±25 84±28 0.41 40-100
E/A 1.00±0.65 1.18±0.97 0.01 0.6-1.4
E´ lateral annulus, cm/sec 9.1±3.5 9.4±3.2 0.35 7.0-11.5
E´ septal annulus, cm/sec 7.4±2.3 7.1±2.5 0.26 5.0-11.0
IVRT, ms 97±22 93±21 0.053 4.5-11.5
E deceleration time 217±78 211±75 0.38 60-130
Left atrial area, cm2 23±6 24±6 0.003 10-20
Enlarged left atria 366 (66%) 140 (75%) 0.02
Left atrial volume Index (LAVI) 44.1±17.8 46.8±19.1 0.15 16-34
RV systolic pressure 26±13 28±14 0.28 15-25
LV hypertrophy – LV mass>140 gram 
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Table 3. Outcomes according to diabetes in I-Preserve
No. 
patients
No.
events
Event rate
per 100 py
Unadjusted HR Adjusted* HRs
CV death or HF 
hospitalization
No history of diabetes 2994 662 (22%) 5.7 (5.3-6.2) 1.00 (ref) 1.00 (ref.)
Diabetes 1134 391 (34%) 10.2 (9.2-11.3) 1.76 (1.55-1.99) 1.75 (1.49-2.05)
CV death
No history of diabetes 2994 393 (13%) 3.2 (2.9-3.5) 1.00 (ref.) 1.00 (ref.)
Diabetes 1134 220 (19%) 5.0 (4.4-5.7) 1.61 (1.36-1.89) 1.59 (1.28-1.96)
HF hospitalization
No history of diabetes 2994 408 (14%) 3.5 (3.2-3.9) 1.00 (ref.) 1.00 (ref.)
Diabetes 1134 253 (22%) 6.6 (5.8-7.5) 1.82 (1.55-2.13) 1.77 (1.45-2.16)
All-cause mortality
No history of diabetes 2994 567 (19%) 4.6 (4.2-5.0) 1.00 (ref.) 1.00 (ref.)
Diabetes 1134 314 (28%) 7.2 (6.4-8.0) 1.59 (1.39-1.83) 1.59 (1.33-1.91)
Non CV death
No history of diabetes 2994 174 (6%) 1.4 (1.2-1.6) 1.00 (ref.) 1.00 (ref.)
Diabetes 1134 94 (8%) 2.1 (1.8-2.6) 1.57 (1.22-2.02) 1.60 (1.14-2.25)
All-cause hospitalization
No history of diabetes 2994 1520 (51%) 17.3 (16.5-18.2) 1.00 (ref.) 1.00 (ref.)
Diabetes 1134 708 (62%) 26.2 (24.3-28.2) 1.45 (1.33-1.59) 1.51 (1.34-1.70)
CV hospitalization
No history of diabetes 2994 815 (27%) 7.8 (7.3-8.4) 1.00 (ref.) 1.00 (ref.)
Diabetes 1134 374 (33%) 10.7 (9.7-11.8) 1.33 (1.17-1.50) 1.34 (1.14-1.57)
Non-CV hospitalization
No history of diabetes 2994 699 (23%) 6.5 (6.0-7.0) 1.00 (ref.) 1.00 (ref)
Diabetes 1134 331 (29%) 9.2 (8.3-10.2) 1.37 (1.21-1.57) 1.41 (1.19-1.68)
HF – heart failure. CV-cardiovascular, Py- person-years, ref - reference
*adjusted for age, sex, quality of life, log NT-proBNP, eGFR, Heart rate, neutrophils, ejection fraction, 
hospitalization for HF in last 6 months, ischemic etiology, Hx myocardial infarction, Hx COPD/Asthma
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Table 4. Outcomes according to diabetes in I-Preserve (only patients with echocardiographic 
data)
No. patients No. events Event rate
per 100 py
Unadjusted HR Adjusted* HRs
CV death or HF 
hospitalization
No history of diabetes 558 96 (17%) 4.8 (3.9-5.9) 1.00 (ref.) 1.00 (ref.)
Diabetes 187 52 (28%) 8.8 (6.7-11.5) 1.79 (1.28-2.51) 1.45 (0.82-2.59)
CV death
No history of diabetes 558 44 (8%) 2.1 (1.5-2.8) 1.00 (ref.) 1.00 (ref.)
Diabetes 187 28 (15%) 4.1 (2.8-6.0) 1.99 (1.24-3.19) 1.84 (0.76-4.45)
HF hospitalization
No history of diabetes 558 61 (11%) 3.1 (2.4-3.9) 1.00 (ref.) 1.00 (ref.)
Diabetes 187 36 (19%) 6.1 (4.4-8.4) 1.94 (1.29-2.93) 1.55 (0.76-3.20) 
All-cause mortality
No history of diabetes 558 74 (13%) 3.5 (2.8-4.4) 1.00 (ref.) 1.00 (ref.)
Diabetes 187 43 (23%) 6.3 (4.7-8.5) 1.82 (1.25-2.65) 2.12 (1.07-4.18)
Non CV death
No history of diabetes 558 30 (5%) 1.4 (1.0-2.0) 1.00 (ref.) 1.00 (ref.)
Diabetes 187 15 (8%) 2.2 (1.3-3.7) 1.57 (0.85-2.93) 3.63 (1.08-12.20)
All-cause hospitalization
No history of diabetes 558 273 (49%) 17.8 (15.8-20.0) 1.00 (ref.) 1.00 (ref.)
Diabetes 187 115 (61%) 28.2 (23.5-33.8) 1.53 (1.23-1.90) 1.50 (1.04-2.18)
CV hospitalization
No history of diabetes 558 133 (24%) 7.2 (6.1-8.6) 1.00 (ref.) 1.00 (ref.)
Diabetes 187 54 (29%) 10.0 (7.7-13.1) 1.34 (0.98-1.84) 1.11 (0.63-1.96)
Non-CV hospitalization
No history of diabetes 558 140 (25%) 7.7 (6.5-9.1) 1.00 (ref.) 1.00 (ref.)
Diabetes 187 61(33%) 11.1 (8.7-14.3) 1.42 (1.05-1.92) 1.64 (1.01-2.67)
Py - person-years, ref – reference
*adjusted for age, sex, quality of life, log NT-proBNP, eGFR, Heart rate, neutrophils, ejection fraction, 
hospitalization for HF in last 6 months, ischemic etiology, Hx myocardial infarction, Hx COPD/Asthma , 
LV end systolic volume, LV mass, ejection fraction, E/E’ ratio, Left atrial area.
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Table 5. Mode of death according to diabetes in I-Preserve
No diabetes (n=2994) Diabetes (n=1134) p-value
Death
All causes 567 (19%) 314 (28%) <0.0001
Cardiovascular 393 (13%) 220 (20%) <0.0001
Pump failure 72 (2%) 53 (5%) 0.0001
Sudden cardiac death 144 (5%) 87 (8%) 0.0004
Myocardial infarction 32 (1%) 13 (1%) 0.83
Stroke 57 (2%) 19 (2%) 0.63
Other cardiovascular 85 (3%) 42 (4%) 0.15
Non-cardiovascular 174 (6%) 94 (8%) 0.004
 by guest on January 5, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.116.024593
24
Figure Legends
Figure 1. Cumulative incidence plot for composite endpoint of cardiovascular death or HF 
hospitalization according to history of diabetes 
Figure 2. Cumulative incidence plot for all-cause mortality according to history of diabetes 
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SUPPLEMENTAL MATERIAL 
Supplementary Table 1:   Baseline Characteristics stratified by history of diabetes among patients 
with full echocardiographic examination 
 All patients 
n=745 
No diabetes 
n=558 
Diabetes 
n=187 
P-value 
Age, mean – years  72±7 72±7 72±7 0.9747 
>/=65 years 480 (64.4%) 271 (49%) 83 (44%) 0.6070 
>/=75 years 265 (36%) 194 (35%) 71 (58%)  
Female sex, no. (%) 459 (62%) 351 (63%) 108 (58%) 0.2102 
Race, no (%):    0.0248 
Caucasian 713 (96%) 537 (96%) 176 (94%)  
Black 12 (2%) 5 (1%) 7 (4%)  
Other 20 (3%) 16 (3%) 5 (3%)  
Ejection fraction 60±9 60±9 60±9 0.5429 
Body mass index 30±5 29±5 32±5 <0.0001 
Underweight (<18.5) 2 (0%) 2 (0%) 0 <0.0001 
Normal (18.5-24.9) 105 (14%) 92 (17%) 13 (7%)  
Overweight (25-29.9) 302 (41%) 239 (43%) 63 (34%)  
Obese (≥30) 336 (45%) 225 (40%) 111 (59%)  
Symptoms     
NYHA class    0.8429 
II 164 (22%) 120 (22%) 44 (24%)  
III 560 (75%) 422 (76%) 138 (74%)  
IV 21 (3%) 16 (3%) 5 (3%)  
Minnesota living with HF, median 40 (27-54) 39 (27-52) 43 (26-58) 0.2623 
     
Examination findings     
Rales 182 (24%) 140 (25%) 42 (23%) 0.4689 
CXR congestion 287 (39%) 205 (37%) 82 (44%) 0.0837 
Jugular venous distention 65 (9%) 43 (8%) 21 (11%) 0.1367 
Edema 448 (60%) 332 (60%) 116 (62%) 0.5402 
3
rd
 heart sound 41 (6%) 32 (6%) 9 (5%) 0.6323 
Heart rate /bpm 70±10 69±10 71±11 0.0937 
Systolic blood pressure /mm Hg 136±15 136±14 137±15 0.4641 
     
ECG findings     
Left bundle branch block  48 (6%) 37 (7%) 11 (6%) 0.7183 
Left ventricular hypertrophy 210 (28%) 161 (29%) 49 (26%) 0.4858 
QRS duration  0.10±0.06 0.10 ± 0.06 0.10 ± 0.07 0.2645 
Atrial fibrillation/flutter  106 (14%) 74 (13%) 32 (17%) 0.1921 
     
Laboratory examinations     
NT-proBNP, median (Q1-Q3) 299 (129-916) 272 (114- 801) 415 (177-1237) 0.0021 
eGFR - l/min/1.73m
2
, median (Q1-Q3) 70 (56-84) 70 (56-84) 70 (56-83) 0.6748 
CKD (eGFR<60 l/min/1.73m
2
) 239 (32%) 179 (32%) 60 (32%) 0.9986 
Hemoglobin, g/dl 14.0±1.4 14.1±1.4 13.7±1.5 0.0020 
Anemia (Hb<11 Women <13 Men) 76 (11%) 48 (9%) 28 (16%) 0.0029 
Neutrophils, cells/µL (Q1-Q3)  4.0 (3.3-5.0) 4.5 (3.5-5.6) 0.0003 
     
Medical history, no. (%)     
HF hospitalization within 6 months 308 (41%) 218 (39%) 90 (48%) 0.0295 
Ischemic etiology 150 (20%) 105 (19%) 45 (24%) 0.1215 
Hypertensive etiology 529 (71%) 408 (73%) 121 (65%) 0.0282 
Myocardial infarction 148 (20%) 103 (19%) 45 (24%) 0.1215 
Stable angina pectoris 277 (37%) 218 (39%) 59 (32%) 0.0656 
Unstable angina pectoris 58 (8%) 41 (7%) 17 (9%) 0.4413 
Hypertension 683 (92%) 507 (91%) 176 (94%) 0.1628 
Atrial fibrillation 192 (26%) 136 (24%) 56 (30%) 0.1315 
Stroke/TIA 77 (10%) 53 (10%) 24 (13%) 0.1947 
PCI or CABG 98 (13%) 68 (12%) 30 (16%) 0.1769 
ICD 0 0 0 NA 
Pacemaker 50 (7%) 31 (6%) 19 (10%) 0.0294 
     
Medication, no. (%)     
Any diuretic 614 (82%) 455 (82%) 159 (85%) 0.2785 
Loop diuretic 371 (50%) 256 (46%) 115 (62%) 0.0002 
ACE-I 227 (31%) 145 (26%) 82 (44%) <0.0001 
Beta-blocker 468 (63%) 356 (64%) 112 (60%) 0.3388 
Calcium-channel blocker 331 (44%) 243 (44%) 88 (47%) 0.4031 
Long-acting nitrates 173 (23%) 129 (23%) 44 (24%) 0.9083 
Mineralocorticoid antagonists 120 (16%) 85 (15%) 35 (19%) 0.2621 
Digoxin 65 (9%) 42 (8%) 23 (12%) 0.0453 
Lipid lowering drugs 179 (24%) 121 (22%) 58 (31%) 0.0097 
Antiplatelets, any 434 (58%) 325 (58%) 109 (58%) 0.9914 
Metformin 53 (28%) 0 (0%) 53 (28%) <0.0001 
Other oral antidiabetic agents 92 (12%) 0 (0%) 92 (49%) <0.0001 
Insulin 47 (6%) 0 (0%) 47 (25%) <0.0001 
HF – heart failure, CXR – chest x-ray, bpm – beats per minute, eGFR – estimated glomerular filtration rate, CKD – 
chronic kidney disease, PCI – percutaneous coronary intervention, CABG  - coronary artery bypass graft, ICD – 
Implantable cardioverter defibrillator 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2:  Comparison of results applying Cox regression and competing risk analyses 
 Event rate 
per 100 py 
Unadjusted HR Unadjusted 
SHR (comp 
risk) 
Adjusted HR Adjusted SHR 
(Comp risk) 
CV death or HF hospitalization      
No history of diabetes 5.7 (5.3-6.2) 1.00 (ref) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
Diabetes 10.2 (9.2-11.3) 1.76 (1.55-1.99) 1.73 (1.53-1.96) 1.75 (1.49-2.05) 1.73 (1.45-2.02) 
      
CV death      
No history of diabetes 3.2 (2.9-3.5) 1.00 (ref) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
Diabetes 5.0 (4.4-5.7) 1.61 (1.36-1.89) 1.58 (1.34-1.86) 1.59 (1.28-1.96) 1.54 (1.24-1.91) 
      
HF hospitalization      
No history of diabetes 3.5 (3.2-3.9) 1.00 (ref) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
Diabetes 6.6 (5.8-7.5) 1.82 (1.55-2.13) 1.75 (1.49-2.04 1.77 (1.45-2.16)  1.69 (1.37-2.08) 
      
All-cause mortality      
No history of diabetes 4.6 (4.2-5.0) 1.00 (ref) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
Diabetes 7.2 (6.4-8.0) 1.59 (1.39-1.83) NA 1.59 (1.33-1.91) NA 
      
Non CV death      
No history of diabetes 1.4 (1.2-1.6) 1.00 (ref) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
Diabetes 2.1 (1.8-2.6) 1.57 (1.22-2.02) 1.48 (1.15-1.90) 1.60 (1.14-2.25) 1.50 (1.07-2.09) 
      
All-cause hospitalization      
No history of diabetes 17.3 (16.5-18.2) 1.00 (ref) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
Diabetes 26.2 (24.3-28.2) 1.45 (1.33-1.59) 1.42 (1.30-1.55) 1.51 (1.34-1.70) 1.46 (1.29-1.64) 
      
CV hospitalization      
No history of diabetes 7.8 (7.3-8.4) 1.00 (ref) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
Diabetes 10.7 (9.7-11.8) 1.33 (1.17-1.50) 1.29 (1.14-1.46) 1.34 (1.14-1.57) 1.29 (1.10-1.52) 
      
Non-CV hospitalization      
No history of diabetes 6.5 (6.0-7.0) 1.00 (ref) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
Diabetes 9.2 (8.3-10.2) 1.37 (1.21-1.57) 1.32 (1.16-1.51) 1.41 (1.19-1.68) 1.36 (1.14-1.62) 
HR – Hazard ratio, SHR – Sub hazard ratios, CV –cardiovascular, HF – heart failure 
 
 
 
 
 
 
 
 
Supplementary Table 3   Outcomes stratified by use of insulin in patients with diabetes 
 
 
 
 
 
 No. 
patients 
No. 
 events 
Event rate 
per 100 py 
Unadjusted HR Adjusted* HR 
CV death or HF hosp.      
No history of diabetes 2994 662 (22%) 5.7 (5.3-6.2) 1.00 (ref) 1.00 (ref) 
Diabetes - non-insulin 795 256 (32%) 9.2 (8.1-10.4) 1.59 (1.37-1.83) 1.71 (1.43-2.04) 
Diabetes insulin treated 339 135 (40%) 12.9 (10.9-15.3) 2.20 (1.83-2.65) 1.85 (1.44-2.40) 
      
CV death      
No history of diabetes 2994 393 (13%) 3.2 (2.9-3.5) 1.00 (ref.) 1.00 (ref.) 
Diabetes - non-insulin 795 145 (18%) 4.6 (3.9-5.4) 1.48 (1.22-1.79) 1.55 (1.22-1.97) 
Diabetes insulin treated 339 75 (22%) 6.0 (4.8-7.6) 1.94 (1.51-2.48) 1.67 (1.19-2.33) 
      
HF hospitalization      
No history of diabetes 2994 408 (14%) 3.5 (3.2-3.9) 1.00 (ref.) 1.00 (ref.) 
Diabetes - non-insulin 795 160 (20%) 5.7 (4.9-6.7) 1.59 (1.32-1.91) 1.70 (1.36-2.13) 
Diabetes insulin treated 339 93 (27%) 8.9 (7.3-10.9) 2.41 (1.93-3.02) 1.94 (1.42-2.65) 
      
All-cause mortality      
No history of diabetes 2994 567 (19%) 4.6 (4.2-5.0) 1.00 (ref.) 1.00 (ref.) 
Diabetes - non-insulin 795 205 (26%)  6.5 (5.7-7.5) 1.45 (1.24-1.70) 1.53 (1.25-1.88) 
Diabetes insulin treated 339 109 (32%)  8.8 (7.3-10.6) 1.96 (1.60-2.41) 1.76 (1.32-2.33) 
      
Non CV death      
No history of diabetes 2994 174 (6%) 1.4 (1.2-1.6) 1.00 (ref.) 1.00 (ref.) 
Diabetes - non-insulin 795 60 (8%) 1.9 (1.5-2.5) 1.37 (1.04-1.86) 1.48 (1.00-2.18) 
Diabetes insulin treated 339 34 (10%) 2.7 (2.0-3.8) 2.03 (1.40-2.93) 1.95 (1.15-3.32) 
      
All-cause hospitalization      
No history of diabetes 2994 1520 (51%) 17.3 (16.5-18.2) 1.00 (ref.) 1.00 (ref.) 
Diabetes - non-insulin 795 459 (58%) 22.2 (20.2-24.3) 1.25 (1.13-1.39) 1.35 (1.18-1.55) 
Diabetes insulin treated 339 248 (73%) 39.0 (34.4-44.1) 2.09 (1.83-2.39) 2.04 (1.70-2.46) 
      
CV hospitalization      
No history of diabetes 2994 815 (27%) 7.8 (7.3-8.4) 1.00 (ref.) 1.00 (ref.) 
Diabetes - non-insulin 795 252 (32%) 9.9 (8.7-11.2) 1.24 (1.08-1.43) 1.37 (1.15-1.63) 
Diabetes insulin treated 339 121 (36%) 12.7 (10.7-15.2) 1.56 (1.29-1.89) 1.27 (0.97-1.65) 
      
Non-CV hospitalization      
No history of diabetes 2994 699 (23%) 6.5 (6.0-7.0) 1.00 (ref.) 1.00 (ref) 
Diabetes - non-insulin 795 204 (26%) 7.6 (6.7-8.8) 1.16 (0.99-1.35) 1.16 (0.94-1.42) 
Diabetes insulin treated 339 127 (37%) 13.7 (11.5-16.3) 2.00 (1.65-2.41) 2.28 (1.76-2.95) 
Supplementary Table 4  Serious adverse events and drug discontinuation according to diabetes 
 No diabetes 
(n=2994) 
Diabetes  
(n=1134) 
p-value 
Serious Adverse events    
Increased potassium 8 (1%) 13 (2%) 0.0027 
Hypotension 33 (2%) 18 (2%) 0.5666 
Chronic kidney disease 64 (4%) 55 (7%) 0.0004 
Dizziness 13 (1%) 7 (1%) 0.7428 
    
Drug discontinuation due to 
adverse event (not death) 
289 (17%) 178 (23%) 0.0008 
 
 
 
